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Introduction Lung cancer is the leading cause of cancer death in the US and disproportionately 
affects African-American men. Screening for lung cancer with LDCT has been shown to reduce 
mortality and is recommended by the USPSTF annually for high-risk populations. Five-year 
survival rate for lung cancer is 19.4% overall, but only 13.9% among African-American men. 
The aim of this systematic review is to determine the effect of differential screening patterns on 
lung cancer mortality and/or survival among Black and White men in the US. 
Methods MEDLINE and CINAHL Plus were searched for studies assessing the effect of 
differential lung cancer screening patterns among Black and White men on overall survival. The 
reviewer selected studies for inclusion based on pre-specified criteria, abstracted relevant data, 
and assessed the quality of included studies. 
Results Across all sources, 1206 titles and abstracts were identified; two studies met full 
eligibility criteria. One study estimated that the number of individuals eligible for screening 
based on current guidelines would decrease from 2016-2030 due to changes in smoking 
prevalence, and estimated a cumulative lung cancer mortality reduction of 3.52% and 16.98% 
for the total population and screened population, respectively. The second study evaluated the 
mortality benefits of nine risk prediction models in comparison to the benefits from current 
screening eligibility guidelines. 
Discussion The studies that met inclusion criteria were both modeling studies that did not 
directly answer the key question. The first study suggested that current guidelines for screening 
may have time-sensitive mortality benefits given the decrease in smoking prevalence, and the 
second study suggested that individualized risk assessment could be superior to current 
screening eligibility guidelines in reducing mortality. More research is needed to explain the 
disparate lung cancer survival and mortality outcomes among Black and White men in the US.  
Keywords: US, United States; LDCT, low dose computed tomography; USPSTF, United States Preventive Services Task 




Lung cancer is the second most common cancer and the leading cause of cancer death 
in the United States (US). The number of new cases of lung and bronchus cancer was 
estimated at 54.9 per 100,000 men and women per year based on data from 2012-2016.1 Lung 
cancer is more common among men than women, affecting African-American men at higher 
rates than all other racial and ethnic groups. According to the most recent Surveillance, 
Epidemiology, and End Results (SEER) program data, the incidence among African-American 
men is 73.5 per 100,000 person-years and the 5-year survival rate is 13.9%.1,2,3 This figure is 
particularly alarming given the relative 5-year survival rate of 19.4% across all gender, race, and 
ethnic groups (Appendix A).1  
According to Healthy People 2020, a health disparity is defined as “a particular type of 
health difference that is closely linked with social, economic, and/or environmental 
disadvantage.” Health disparities adversely affect groups of people who have systematically 
experienced greater obstacles to health based on their racial or ethnic group; religion; 
socioeconomic status; gender; age; mental health; cognitive, sensory, or physical disability; 
sexual orientation or gender identity; geographic location; or other characteristics historically 
linked to discrimination or exclusion”.4  In identifying the social constructs that contribute to poor 
health outcomes among certain populations, Healthy People 2020 established initiatives “to 
achieve health equity, eliminate disparities, and improve the health of all groups”.4 Prior studies 
have shown that racial disparities in lung cancer incidence and mortality are associated with 
poorer access to care, greater exposure to environmental hazards, and the underrepresentation 
of African-Americans in cancer clinical trials.5 These disparities may emerge from any stage of 
detection and management—including cancer screening, a point along the continuum with 
proven potential to reduce health disparities. 
The National Lung Screening Trial (NLST) found that low dose computed tomography 
(LDCT) screening reduces lung cancer specific mortality by 20% among high-risk individuals in 
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comparison to screening with chest radiography alone.6 Follow-up studies have suggested that 
black individuals may benefit the most from screening for this purpose.7 In 2013, the US 
Preventive Services Task Force (USPSTF) made recommendations to screen for lung cancer 
with an annual LDCT scan in adults aged 55 to 80 years with a 30-pack year smoking history 
who currently smoke or quit smoking within the last 15 years.8 In comparison to their White male 
counterparts, African-American men are more likely to be diagnosed with lung cancer at a later 
stage and this finding may be related to differential cancer screening patterns between the two 
groups. The cancer stage at the time of diagnosis has direct implications for types of treatment 
options that are available and this is particularly important because surgical resection of early-
stage tumors is associated with improved survival rates.7 Several reports describe the role of 
advanced cancer stage in predicting 5-year survival, but it’s not clear whether differential 
screening patterns, specifically, predict mortality and/or survival. Therefore, the aim of this 
review is to examine the differential patterns of lung cancer screening as a potential source of 




This review follows the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) 2009 checklist guidelines and addresses the following key question: How 
do differences in lung cancer screening practices influence mortality and/or survivorship among 
African-American men compared to White men in the United States? Of note, the investigator 
defines survival as the time between the date of diagnosis and the date of death. The terms 
“survivorship” and “survival rate” are meant to be interpreted in the same manner and are 
described as the 5-year survival rate for the purposes of this report. Similarly, the terms 
“African-American” and “Black” are used interchangeably. 
Study selection 
Inclusion and exclusion criteria were developed based on the study population, 
exposure, comparator, outcomes, setting, language, and study designs for the above listed key 
question and are summarized in Appendix B. Eligible populations included African-American 
(Black) or White (non-Black) men in the United States with exposure to lung cancer screening or 
LDCT scan for lung cancer screening. The specific exposure of interest is lung cancer screening 
with a LDCT scan. The USPSTF first recommended annual LDCT screening for lung cancer in 
high-risk populations on December 31, 2013. Prior to this recommendation, screening for lung 
cancer was left primarily to the health care provider’s discretion.  Given the historical reports of 
African-Americans utilizing cancer-screening modalities at lower rates than other ethnic 
minorities, the investigator used “lung cancer screening” more broadly as the exposure of 
interest to capture the maximum number of eligible studies. The primary outcomes were the 
rates of mortality and/or survival. 
The most rigorous evidence in support of lung cancer screening as a predictor of 
reduced mortality (and/or improved survival) would come in the form of a randomized controlled 
trial (RCT) and this association has already been reported previously in the literature.6 Few 
studies, however, directly examine the differential use of cancer screening tests among different 
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populations as a predictor of mortality and/or survival. For this reason, the investigator broadly 
set pre-defined criteria for eligible study designs to include RCTs, nonrandomized control trials, 
prospective or retrospective cohort studies, and modeling studies. Non-systematic reviews, 
commentaries, opinions, or editorials/letters to the editor were excluded (Appendix B). 
Information sources and search strategy 
The investigator met with two health science librarians to develop an appropriate search 
strategy to answer the key question. The investigator used Medical Subject Headings (MeSH) to 
search the MEDLINE database for articles with the appropriate populations, exposures, 
outcomes, and study designs. Search terms included a variation of the following basic key terms 
and phrases: “lung cancer” + “lung cancer screening” + “early detection of cancer” + “CT scan” 
+ “mortality” + “survival rate” + “death rate” + “outcomes” + “African-American men” + “health 
disparities” + “race” and/or “ethnicity”. A similar combination of key terms was used to search 
the Cumulative Index of Nursing and Allied Health Literature (CINAHL) Plus database. The 
complete details of the search strategy are outlined in Appendix C. In order to increase the yield 
of results, there were no time limitations set for the publication of eligible studies.  
The results from each database were imported into a desktop version of a citation 
manager (Mendeley) and uploaded to a web-based systematic review tool (Covidence) for title 
and abstract review. Those marked for potential inclusion were retrieved for evaluation of the full 
text, which were then reviewed by the sole investigator to determine final inclusion or exclusion. 
The investigator hand searched the reference lists of all included studies to ensure that no 
relevant studies were missed.  
Data extraction and quality assessment 
Following full text review, relevant study characteristics were abstracted from each 
included study using a data collection instrument adapted from the aforementioned web-based 
systematic review tool (Covidence) and developed by the investigator. When applicable, the 
following items were abstracted from each study: methods (including the study design); baseline 
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characteristics of the population; inclusion and exclusion criteria; interventions; outcomes; and 
any available identifying information.  
The investigator evaluated the risk of bias for each study by using the Prediction Model 
Risk of Bias Assessment Tool (PROBAST).9 This tool consists of four domains (Participants, 
Predictors, Outcome, and Analysis) that contain signaling questions to facilitate risk of bias 
assessment. Signaling questions are rated as yes (Y), probably yes (PY), probably no (PN), no 
(N), or no information (NI), and each signaling question is phrased so that “yes” indicates the 
absence of bias.10 The overall risk of bias judgment is then rated as “low risk”, “high risk”, or 
“unclear risk” depending on the response for each of the four domains. Similarly, the overall 
judgment for applicability concerns is rated as “low”, “high”, or “unclear”. In instances where the 
answers to signaling questions were “no” or “probably no”, the investigator used her judgment to 
determine the domain rating. A detailed description of the domains and their signaling questions 
is available in Appendix D, and Table 1 provides an explanation of how the overall judgments 
are determined using this tool. This tool was chosen based on the design of included studies 
(prediction models).  
Table 1. PROBAST Ratings  
Reaching an overall judgment about risk of bias of the prediction model evaluation  
Low risk 
of bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external validation, and it was rated as low 
risk of bias for all domains, consider downgrading to high risk of bias. Such a model can 
only be considered as low risk of bias, if the development was based on a very large data set 
and included some form of internal validation.  
High risk 




If an unclear risk of bias was noted in at least one domain and it was low risk for all other 
domains.  
Reaching an overall judgment about applicability of the prediction model evaluation  
Low concerns 
regarding applicability  
If low concerns regarding applicability for all domains, the prediction model 
evaluation is judged to have low concerns regarding applicability.  
High concerns 
regarding applicability  
If high concerns regarding applicability for at least one domain, the prediction 
model evaluation is judged to have high concerns regarding applicability.  
Unclear concerns 
regarding applicability  
If unclear concerns (but no “high concern”) regarding applicability for at least one 
domain, the prediction model evaluation is judged to have unclear concerns 
regarding applicability overall.  
PROBAST, Prediction Model Risk of Bias Assessment Tool 11 
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Data synthesis and analysis 
The investigator developed a qualitative synthesis of the evidence based on the 
outcomes and risk of bias assessments of the included studies. Meta-analyses were not 
conducted given the limited number of included studies. 
Funding 






Across all sources, a yield of 1206 articles was obtained. After de-duplication, 1185 
articles with unique results were included for title and abstract review with 33 articles being 
eligible for full-text review. Two articles met full eligibility criteria and are included in this analysis 
(Figure 1). The characteristics of the two studies are summarized in Table 2. Both of the studies 
were modeling studies that reported on the candidate selection process for lung cancer 
screening, but neither study directly addressed the key question. The studies are included in 
this systematic review because they provide insight on screening eligibility criteria, which could 
potentially influence future work in health disparities research.   
The Lung Cancer Policy Model (LCPM) [a well-validated, comprehensive Monte Carlo 
micro-simulation model of non-small cell lung cancer and small cell lung cancer development, 
progression, detection, treatment, and survival] was used by Criss et al in conjunction with 
current US smoking trends and Centers for Medicare and Medicaid Services (CMS) lung cancer 
screening guidelines to predict the benefits and harms of LDCT screening among at risk 
groups.13 The outcomes were cumulative mortality reduction, life-years gained, and rates of 
over-diagnosis. All simulated individuals aged 30-84 were followed from 2016 to 2020, with the 
intervention group being modeled to receive annual LDCT scans at a “realistic” screening 
adherence rate of 45% and the control group modeled to receive no lung cancer screening. This 
“realistic” adherence rate was based on reporting from programs indicating lung cancer 
screening adherence rates ranging from 35 to 50%, and further supported by adherence rates 
for established screening programs such as colorectal, breast, cervical, and prostate cancer 
which had adherence rates of 54.6%, 69.3%, 85.8%, and 46.4%, respectively.13 Twenty runs 
were completed to estimate the variability of the micro-simulation model and the means and 
95% confidence intervals are reported.  
In the absence of screening, lung cancer cases were estimated to decrease by 21.90% 
from 180,673 cases in 2016 to 141,114 cases in 2030 resulting in 2,462,479 (95% CI 2,459,751 
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– 2,465,237) cumulative lung cancer cases over the study period. The model projected 
1,777,444 (95% CI 1,775,138 – 1,779,151) cumulative lung cancer deaths between 2016 and 
2030 for all birth cohorts in the US, with former, current, and never smokers totaling 53.60%, 
38.65%, and 7.75% of total lung cancer deaths, respectively. Under CMS screening guidelines, 
cumulative screens through 2030 were estimated to reach 63,857,158 (95% CI 63,815,984–
63,898,332). Annual screens were projected to decrease throughout this time period, owing in 
large part to the changes in smoking patterns among at risk groups (Table 3). For the purposes 
of this study, mortality reduction was defined as “the difference in lung cancer deaths between 
the no-screening and screening scenarios (i.e., deaths avoided), divided by the deaths in the 
no-screening scenario, giving the percentage of deaths in the no-screening scenario that could 
be avoided through screening”.13 Among those individuals who were screened at least once, 
there was an estimated cumulative mortality reduction of 16.98% (95% CI 16.90% - 17.07%). 
However, the total cumulative mortality reduction for the entire study population was estimated 
to be 3.52% (95% CI 3.50% - 3.53%) by 2030. The authors of this study also provide stratified 
estimates for cumulative mortality reduction based on smoker type, gender, and birth cohort. 
The relevant results from these estimates show that current and former male smokers have 
cumulative mortality reductions of 5% and 3.4%, respectively. Other outcomes (i.e. life-years 
gained and over-diagnosis rate) are reported in Table 3 for completeness, but discussion of 
these findings is beyond the scope of this systematic review.  
The study by Haaf et al sought to provide evidence for the use of individualized risk 
criteria in the selection of lung cancer screening candidates. In this study, a retrospective 
validation approach was used to evaluate the performance of nine previously developed risk 
models. Secondary data from the NLST and PLCO trials (Appendix E) were used to assess 
each model for its degree of calibration, discrimination, and clinical usefulness in predicting lung 
cancer incidence and mortality risk (Table 4). The performance of each model was assessed in 
each trial arm, for both lung cancer incidence and lung cancer mortality to minimize the 
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differential effects of screening on outcomes. For instance, screening has the potential to affect 
a model’s predictive performance for lung cancer incidence due to phenomena such as lead-
time bias or over-diagnosis.14 All models included age and various measures of smoking 
exposure (smoking status, smoking duration, cigarettes per day, pack-years smoked, time since 
smoking cessation) as risk predictors, while some models accounted for factors such as gender, 
race, ethnicity, presence of comorbid respiratory disease, and personal history of cancer. A 
variety of follow-up durations were used to investigate the effect of follow-up duration on the 
discrimination performance of each model. A final evaluation was made to estimate the 
sensitivity and specificity of each model in comparison to NLST criteria for specific thresholds. 
This was done to estimate whether any of the models were more sensitive or specific in 
detecting lung cancer compared to the current NLST criteria (which inform CMS guidelines for 
lung cancer screening). Of note, the performance of each risk prediction model was evaluated 
based on the manner that it was presented in its original publication, without any recalibration 
re-parameterization to the NLST or PLCO. The only exception was the PLCOm2012 model, 
which was originally developed on data from the control arm of the PLCO trial. Analyses for this 
study were performed with multiple imputation of missing values.14 
Numerical data for calibration, discrimination, and clinical usefulness are available in 
Appendix F. Overall, all models showed “satisfactory calibration performance” and the 
calibration was better for all models in the PLCO datasets than the NLST datasets.14 “The 
discriminative performance of the models was better in the PLCO datasets (AUCs ranging from 
0.74 to 0.81) than in the NLST datasets (AUCs ranging from 0.61 to 0.73), and the 
discriminative performance of most models was better for lung cancer mortality than lung cancer 
incidence. The PLCOm2012 model (and its simplified version), the Bach model, and the TSCE 
incidence model showed the best discriminative performance across all datasets regardless of 
the type of predicted outcome”.14, pp12 Decision curve analyses provided a range of upper and 
lower risk thresholds that yielded an overall positive net benefit for each model compared with 
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the NLST eligibility criteria. Although the ranges varied among each model, they were roughly 
consistent across all models ranging from approximately 0.1% to 16.7%.14 The sensitivity and 
specificity of each of the risk prediction models was higher than those of the NLST criteria. The 
PCLOm2012 model, followed by the Bach and TSCE incidence model had the highest 
sensitivities (all three models >79.8%) and specificities (all three models >62.3%) of all.14  
The investigator judged the study by Criss et al to have a low risk of bias with low 
concerns for applicability. There was low suspicion for selection bias because it seemed 
reasonable to only include individuals who met the current lung cancer screening guidelines, 
even when considering that the CMS lung cancer screening guidelines may not accurately 
capture all high-risk groups. However, the study by Haaf et al was judged to have a high risk of 
bias with low concerns for applicability. This was primarily due to the absence of a uniform 
definition of the predictors across all models and the failure to re-calibrate the models to the 
NLST or PLCO data. Additionally, some models included predictors that did not have supporting 
data from the NLST and PLCO trials. In those instances, the investigators assumed no 
exposure, which could lead to biased estimates. A more detailed risk of bias assessment for 
each study is available in Appendix G. 
Synthesis of Results 
Although there is a strong body of evidence in favor of screening as strategy to decrease 
lung cancer mortality among high-risk groups, neither of the studies included in this review 
directly answered the key question. However, there was some homogeneity in regards to the 
outcomes reported as both studies highlighted the challenges of appropriately categorizing a 
patient as “high-risk” so that he is eligible for lung cancer screening. The first study suggested 
that current CMS guidelines (which are based on only age, pack-year smoking history, and time 
since cessation) for lung cancer screening may have time-sensitive mortality benefits given the 
decrease in smoking prevalence among younger generations, and the second study suggested 
that individualized risk assessment may be superior to current screening guidelines in reducing 
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lung cancer mortality. The results of this review indicate that there is limited high-quality 
evidence directly supporting differential patterns in lung cancer screening as being a primary 
driver of disparate mortality outcomes among African-American and White men in the US. 
	











































Adapted from:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097.
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The aim of this review was to examine the differential patterns of lung cancer screening 
as a potential source of disparities in lung cancer mortality and/or survival among African-
American and White men in the US. Although neither of the studies that were included in this 
analysis directly answers the key question, they each provide some insight into potential 
solutions to reduce health disparities in lung cancer outcomes.  
The study by Criss et al estimated the benefits and harms of LDCT screening among a 
group with a realistic screening adherence rate (45%) and a group without any screening over 
the years 2016-2030. The findings suggested that the number of individuals eligible for lung 
cancer screening (under current CMS guidelines) between the years 2016-2030 will likely 
decrease due to changes in smoking prevalence among younger cohorts in the US and 
estimated a cumulative lung cancer mortality reduction of 3.52% and 16.98% for the total 
population and screened population, respectively. These findings suggest that we should tailor 
our efforts towards improving screening adherence if we wish to see mortality benefits in the 
short-term, and target these efforts to only high-risk groups to minimize the harms of over-
diagnosis in the long-term. Of note, the model used in this study analyzed the US population at 
large and did not account for race or socioeconomic status in its projections of lung cancer 
screening health outcomes. Although the authors addressed this issue, it further highlights the 
limited evidence on causes of disparate lung cancer outcomes among African-American and 
White men in the US. 
The study by Haaf et al provided evidence that the selection of lung cancer screening 
candidates could be improved through the application of risk prediction modeling, which offers a 
more individualized assessment. The study population was inclusive of all participants from the 
NLST trial and all ever-smoking persons from the PLCO trial. However, the predictors in this 
study did not have a uniform definition across all models and only one model accounted for race 
(PLCOm2012 model).  Each of the lung cancer risk prediction models showed satisfactory 
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calibration and discrimination performance, and the decision curve analysis for each model 
yielded an overall positive net benefit in comparison to the NLST eligibility criteria. This 
suggests that assessment of screening eligibility with current criteria and risk prediction 
modeling is superior to using only age, pack-year history, and time since cessation alone. This 
improvement to the selection process could reduce lung cancer mortality in the long-term, 
particularly among ethnic minorities who often do not meet the pack-year history and time since 
cessation requirements to be eligible for LDCT screening. 
Overall, the literature base for this review was extremely limited and neither of the 
studies that met inclusion criteria directly answered the key question. However, the results of 
these studies complement ongoing health disparity research by highlighting the limited 
knowledge in this area and by providing evidence that more individualized assessment 
strategies in the selection of screening candidates is an avenue for further exploration. 
Limitations of the review 
The major limitation of this systematic review is that a single investigator performed the 
title and abstract review, full text review, data extraction, and quality assessment without the 
opportunity to reconcile any uncertainties among a group of co-investigators. The evidence 
base surrounding the key question was also extremely limited, but this could be in part due to 
publication bias as the investigator did not search the gray literature. When considering the 
complexities that come with conducting research on a subject related to disparate health 
outcomes and the social constructs potentially leading to them, it is reasonable to assume that 
more literature exists in academic databases not strictly intended for medical use. 
Implications for future research 
The results from this review suggest that current lung cancer screening practices (in 
which eligibility for LDCT is based on only age, pack-year history, and time since cessation) 
may have time-limited benefits. The prevalence of smoking in the US is declining and with that 
so is the future risk-pool of eligible screening candidates. In order to achieve the maximum 
mortality benefits of LDCT while still limiting the potential for over-diagnosis, clinicians should 
	 24 
consider incorporating individualized risk assessment models in their selection of candidates to 
be screened for lung cancer. 
There is still much to be done to close the gap in survival and mortality among African-
American and White men with lung cancer in the US. Based on the studies included in this 
review, it is apparent that individual characteristics (such as smoking status at the time of 
screening and the intensity of smoking) are perhaps equally important in predicting who is most 
likely to develop and/or die from lung cancer. Prior studies have reported on the differential 
smoking patterns among ethnic minorities in the US (compared to their White counterparts) and 
this may offer an opportunity to employ more targeted research in this area.13 Until the primary 
drivers of lung cancer survival and mortality disparities are better understood, it is essential that 
clinicians make intentional efforts to ensure that the use of any individualized risk assessment 
model does not further marginalize ethnic minorities.
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Appendix A: Surveillance, Epidemiology, and End Results (SEER) Program Data among 
males in the United States with Lung & Bronchus Cancer 
 







Whites 63.5 51.7 16.2 
 




   
Whites -3.0* -3.4*  
Blacks -3.4* -4.0*  
Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US std 
population (19 age groups – Census P25-1130). Overall trend is reported in annual percent 
change (APC) over the time interval.2,3 
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Appendix D: PROBAST Assessment Tool  
(SOURCE: http://development.probast.org/Portals/0/Documents/PROBAST_20190515.pdf)11 
DEV= development, VAL= validation 
 
DOMAIN 1: Participants  
Covers potential sources of bias and applicability concerns related to the data sources used and how 
participants were selected for enrollment into the study 
 
A. Risk of Bias  
Describe the sources of data and criteria for participant selection:  
 Dev  Val  
1.1 Were appropriate data sources used, e.g. cohort, RCT or nested case-control study data?    
1.2 Were all inclusions and exclusions of participants appropriate?    
Risk of bias introduced by selection of participants  
RISK:  
(low/ high/ unclear)  
  
Rationale of bias rating:  
B. Applicability  
Describe included participants, setting and dates:  
Concern that the included participants and setting do not match the 
review question  
CONCERN:  
(low/ high/ unclear)  
  
Rationale of applicability rating:  
 
 
DOMAIN 2: Predictors  
Covers potential sources of bias and applicability concerns related to the definition and measurement of 
predictors. Predictors are variables evaluated for their association with the outcome of interest; they are 
ultimately combined to form the prediction model 
 
A. Risk of Bias  
List and describe predictors included in the final model, e.g. definition and timing of assessment:  
 Dev  Val  
2.1 Were predictors defined and assessed in a similar way for all participants?    
2.2 Were predictor assessments made without knowledge of outcome data?    
2.3 Are all predictors available at the time the model is intended to be used?    
Risk of bias introduced by predictors or their assessment  
RISK:  
(low/ high/ unclear)  
  
Rationale of bias rating:  
B. Applicability  
Concern that the definition, assessment or timing of predictors in the model 
do not match the review question  
CONCERN:  
(low/ high/ unclear)  
  
Rationale of applicability rating:  
	 33 
 
DOMAIN 3: Outcome  
Covers potential sources of bias and applicability concerns related to the definition and determination of 
the outcome 
 
A. Risk of Bias  
Describe the outcome, how it was defined and determined, and the time interval between predictor 
assessment and outcome determination:  
 Dev  Val  
3.1 Was the outcome determined appropriately?    
3.2 Was a pre-specified or standard outcome definition used?    
3.3 Were predictors excluded from the outcome definition?    
3.4 Was the outcome defined and determined in a similar way for all participants?    
3.5 Was the outcome determined without knowledge of predictor information?    
3.6 Was the time interval between predictor assessment and outcome determination appropriate?    





Rationale of bias rating:  
B. Applicability  
At what time point was the outcome determined:  
If a composite outcome was used, describe the relative frequency/distribution of each contributing 
outcome:  
Concern that the outcome, its definition, timing or determination do not 









DOMAIN 4: Analysis  
Examines whether key statistical considerations were correctly addressed 
 
Risk of Bias  
Describe numbers of participants, number of candidate predictors, outcome events and events per 
candidate predictor:  
Describe how the model was developed (for example in regards to modeling technique (e.g. survival or 
logistic modeling), predictor selection, and risk group definition):  
Describe whether and how the model was validated, either internally (e.g. bootstrapping, cross validation, 
random split sample) or externally (e.g. temporal validation, geographical validation, different setting, 
different type of participants):  
Describe the performance measures of the model, e.g. (re)calibration, discrimination, (re)classification, 
net benefit, and whether they were adjusted for optimism:  
Describe any participants who were excluded from the analysis:  
Describe missing data on predictors and outcomes as well as methods used for missing data:  
 Dev  Val  
4.1 Were there a reasonable number of participants with the outcome?    
4.2 Were continuous and categorical predictors handled appropriately?    
4.3 Were all enrolled participants included in the analysis?    
4.4 Were participants with missing data handled appropriately?    
4.5 Was selection of predictors based on univariable analysis avoided?    
4.6 Were complexities in the data (e.g. censoring, competing risks, sampling of controls) 
accounted for appropriately?    
4.7 Were relevant model performance measures evaluated appropriately?    
4.8 Were model overfitting and optimism in model performance accounted for?    
4.9 Do predictors and their assigned weights in the final model correspond to the results 
from multivariable analysis?    
Risk of bias introduced by the analysis  
RISK:  
(low/ high/ unclear)  
  
Rationale of bias rating:  
	
 
Reaching an overall judgment about risk of bias of the prediction model evaluation  
Low risk 
of bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external validation, and it was rated as low 
risk of bias for all domains, consider downgrading to high risk of bias. Such a model can 
only be considered as low risk of bias, if the development was based on a very large data set 
and included some form of internal validation.  
High risk 




If an unclear risk of bias was noted in at least one domain and it was low risk for all other 
domains.  
Reaching an overall judgment about applicability of the prediction model evaluation  
Low concerns 
regarding applicability  
If low concerns regarding applicability for all domains, the prediction model 
evaluation is judged to have low concerns regarding applicability.  
High concerns 
regarding applicability  
If high concerns regarding applicability for at least one domain, the prediction 
model evaluation is judged to have high concerns regarding applicability.  
Unclear concerns 
regarding applicability  
If unclear concerns (but no “high concern”) regarding applicability for at least one 
domain, the prediction model evaluation is judged to have unclear concerns 
regarding applicability overall.  
 
Overall judgment about risk of bias and applicability of the prediction model evaluation  
Overall judgment of risk of bias  
RISK:  
(low/ high/ unclear)  
 
Summary of sources of potential bias:  
 
Overall judgment of applicability  
CONCERN:  
(low/ high/ unclear)  
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Appendix G: Detailed Risk of Bias Assessments using PROBAST Tool 
 
Study 1. Population Impact of Lung Cancer Screening in the US (Criss et al)  
 
DEV=development; VAL=validation 
DOMAIN 1: Participants  
Covers potential sources of bias and applicability concerns related to the data sources used and how 
participants were selected for enrollment into the study 
 
A. Risk of Bias  
Describe the sources of data and criteria for participant selection: US census population meeting current 
CMS guidelines for lung cancer screening (current or former smoker with at least 30 pack-years of 
smoking and fewer than 15 years since quitting, and aged 55-77 years within the projected time period of 
2016 to 2030)  
 Dev  Val  
1.1 Were appropriate data sources used, e.g. cohort, RCT or nested case-control study data?   Y 
1.2 Were all inclusions and exclusions of participants appropriate?   Y 
Risk of bias introduced by selection of participants  
RISK:  
(low/ high/ unclear)  
 low 
Rationale of bias rating: It seems reasonable to only include those who would be at risk for developing or 
dying from lung cancer. However, the CMS guidelines may not accurately capture all at risk groups with 
the current lung cancer screening criteria. 
B. Applicability  
Describe included participants, setting and dates:  
Must be a current or former smoker with at least 30 pack-years of smoking and fewer than 15 years since 
quitting, aged 55-77 years in the US within the projected time period of 2016 to 2030 
Concern that the included participants and setting do not match 
the review question  
CONCERN:  
(low/ high/ unclear)  
 low 
















DOMAIN 2: Predictors  
Covers potential sources of bias and applicability concerns related to the definition and measurement of 
predictors. Predictors are variables evaluated for their association with the outcome of interest; they are 
ultimately combined to form the prediction model 
 
A. Risk of Bias  
List and describe predictors included in the final model, e.g. definition and timing of assessment:  
Characteristics of the simulated population (e.g., birth year, smoking history, and smoking-adjusted 
mortality risk from competing causes) and scenario-specific items (e.g., test characteristics, screening 
program characteristics, screen adherence and eligibility, and response rates for treatments). Individual-
level characteristics specific to the US population, such as age of smoking initiation, cigarettes smoked 
per day, and age of smoking cessation, were modeled using the “smoking history generator,” provided by 
the National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET)  
 
 Dev  Val  
2.1 Were predictors defined and assessed in a similar way for all participants?   PY 
2.2 Were predictor assessments made without knowledge of outcome data?   PY 
2.3 Are all predictors available at the time the model is intended to be used?   PY 
Risk of bias introduced by predictors or their assessment  
RISK:  
(low/ high/ unclear)  
 low 
Rationale of bias rating: Predictor information was modeled from credible sources  
B. Applicability  
Concern that the definition, assessment or timing of predictors in the 
model do not match the review question  
CONCERN:  
(low/ high/ unclear)  
 low 





















DOMAIN 3: Outcome  
Covers potential sources of bias and applicability concerns related to the definition and determination of 
the outcome 
 
A. Risk of Bias  
Describe the outcome, how it was defined and determined, and the time interval between predictor 
assessment and outcome determination:  
The outcomes reported were cumulative mortality reduction, life-years gained, and the over-diagnosis 
rate.  
 
Mortality reduction is defined as the difference in lung cancer deaths between the no-screening and 
screening scenarios (i.e., deaths avoided), divided by the deaths in the no-screening scenario, giving the 
percentage of deaths in the no-screening scenario that could be avoided through screening. 
 
Over-diagnosed cases in this study are defined as those in which an individual is screened and 
subsequently diagnosed with lung cancer but eventually dies of causes other than lung cancer. These are 
deemed over-diagnoses because these additional lung cancer diagnoses that occur in the screening 
scenario compared to the no-screening scenario would have likely had limited negative consequences if 
they had remained undetected because of absence of screening. 
 
There was no description of how “life-years gained” was determined. 
 Dev  Val  
3.1 Was the outcome determined appropriately?   Y 
3.2 Was a pre-specified or standard outcome definition used?   Y 
3.3 Were predictors excluded from the outcome definition?   PY 
3.4 Was the outcome defined and determined in a similar way for all participants?   Y 
3.5 Was the outcome determined without knowledge of predictor information?   PY 
3.6 Was the time interval between predictor assessment and outcome determination 
appropriate?   Y 
Risk of bias introduced by the outcome or its determination  
RISK:  
(low/ high/ unclear)  
 low 
Rationale of bias rating: The reported outcome definitions seem reasonable  
B. Applicability  
At what time point was the outcome determined: This was a micro-simulation study for the years 2016-
2030 
If a composite outcome was used, describe the relative frequency/distribution of each contributing 
outcome:	N/A	
Concern that the outcome, its definition, timing or determination do 
not match the review question  
CONCERN:  
(low/ high/ unclear)  
 low 
Rationale of applicability rating: The study simulated outcomes for the future (2016-2030) based on 
current US census data. If the investigators had some knowledge of the predictor information the results 





DOMAIN 4: Analysis  
Examines whether key statistical considerations were correctly addressed 
 
Risk of Bias  
Describe numbers of participants, number of candidate predictors, outcome events and events per 
candidate predictor (for DEV only): N/A 
Describe how the model was developed (for example in regards to modeling technique (e.g. survival or 
logistic modeling), predictor selection, and risk group definition): N/A, validation study only 
Describe whether and how the model was validated, either internally (e.g. bootstrapping, cross validation, 
random split sample) or externally (e.g. temporal validation, geographical validation, different setting, 
different type of participants):  
LCPM is a well-validated, comprehensive Monte Carlo micro-simulation model of non-small cell lung 
cancer (NSCLC) and small cell lung cancer (SCLC) development, progression, detection, treatment, and 
survival. The LCPM simulates progression, detection, follow-up, treatment, and survival of individual 
patients using a state-transition micro-simulation method. In the LCPM, lung cancer patients can develop 
adenocarcinoma (including adenocarcinoma in situ), large cell carcinoma, squamous cell carcinoma, 
small cell carcinoma, or other lung cancer. Histologic type informs lung cancer risks, incidence rates, and 
disease progression rates. Natural history parameters have been established through calibration to 
patient-level data from the NLST, and model outputs were validated using data from the Prostate, Lung, 
Colorectal and Ovarian Cancer Screening Trial (PLCO).  
 
Describe the performance measures of the model, e.g. (re)calibration, discrimination, (re)classification, 
net benefit, and whether they were adjusted for optimism:  
LCPM was not directly reported in the article, but was referenced in the S1 appendix.  
Natural history parameters were calibrated to patient-level data from the NLST, and model outputs were 
validated using data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO). 
Describe any participants who were excluded from the analysis: N/A 
Describe missing data on predictors and outcomes as well as methods used for missing data: N/A 
 Dev  Val  
4.1 Were there a reasonable number of participants with the outcome?   Y 
4.2 Were continuous and categorical predictors handled appropriately?   NI 
4.3 Were all enrolled participants included in the analysis?   Y 
4.4 Were participants with missing data handled appropriately?   PY 
4.5 Was selection of predictors based on univariable analysis avoided?    
4.6 Were complexities in the data (e.g. censoring, competing risks, sampling of controls) 
accounted for appropriately?   PY 
4.7 Were relevant model performance measures evaluated appropriately?   PY 
4.8 Were model overfitting and optimism in model performance accounted for?    
4.9 Do predictors and their assigned weights in the final model correspond to the results 
from multivariable analysis?    
Risk of bias introduced by the analysis  
RISK:  
(low/ high/ unclear)  
 low 
Rationale of bias rating: The authors used a well-validated model to simulate the potential effects of 
screening (versus not screening) individuals at high-risk of lung cancer.   
 
	 49 
Reaching an overall judgment about risk of bias of the prediction model evaluation  
Low risk 
of bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external validation, and it was rated as low 
risk of bias for all domains, consider downgrading to high risk of bias. Such a model can 
only be considered as low risk of bias, if the development was based on a very large data set 
and included some form of internal validation.  
High risk 




If an unclear risk of bias was noted in at least one domain and it was low risk for all other 
domains.  
Reaching an overall judgment about applicability of the prediction model evaluation  
Low concerns 
regarding applicability  
If low concerns regarding applicability for all domains, the prediction model 
evaluation is judged to have low concerns regarding applicability.  
High concerns 
regarding applicability  
If high concerns regarding applicability for at least one domain, the prediction 
model evaluation is judged to have high concerns regarding applicability.  
Unclear concerns 
regarding applicability  
If unclear concerns (but no “high concern”) regarding applicability for at least one 
domain, the prediction model evaluation is judged to have unclear concerns 
regarding applicability overall.  
 
Overall judgment about risk of bias and applicability of the prediction model evaluation  
Overall judgment of risk of bias  
RISK:  
(low/ high/ unclear)  
 
Summary of sources of potential bias:  
It seems reasonable to only include those who would be at risk for developing or dying from lung cancer 
as participants in the study. Although the CMS guidelines may not accurately capture all at risk groups, I 
have a low concern for selection bias in this study. The predictor information was modeled from credible 
sources and outcomes were simulated by a well-validated model. 
 
Overall judgment of applicability  
CONCERN:  
(low/ high/ unclear)  
 
Summary of applicability concerns:  
The study simulated outcomes for the future (2016-2030) based on current US census data. If the 












Study 2. Risk Models for Selection of Lung Cancer Screening Candidates (Haaf et al) 
 
DEV=development; VAL=validation 
DOMAIN 1: Participants  
Covers potential sources of bias and applicability concerns related to the data sources used and how 
participants were selected for enrollment into the study 
 
A. Risk of Bias  
Describe the sources of data and criteria for participant selection:  
The study was performed by using secondary data from the National Lung Screening Trial and the 
Prostate, Lung, Colorectal, and Ovarian Cancer Trial (two RCTs) to compare the ability of nine previously 
developed models to predict lung cancer incidence or lung cancer mortality. 
NLST: All participants in the CT arm (n = 26,722) and chest radiography (CXR) arm (n = 26,730)  
PLCO: all ever-smoking participants in the CXR arm (n = 40,600) and control arm (n = 40,072) 
 
Data on the predictor variables in each trial were collected through epidemiologic questionnaires at study 
entry, and harmonized across both trials (no direct influence in the actual selection of participants, but 
these self-reported data were used later on for modeling purposes)	
 Dev  Val  
1.1 Were appropriate data sources used, e.g. cohort, RCT or nested case-control study data?   Y 
1.2 Were all inclusions and exclusions of participants appropriate?   Y 
Risk of bias introduced by selection of participants  
RISK:  
(low/ high/ unclear)  
 low 
Rationale of bias rating:  
It seems reasonable to compare predictive models for lung cancer incidence among groups of individuals 
at high risk for cancer, so it made sense to exclude never smokers from the PLCO trial. A potential 
problem specific to this systematic review is the low percentage of black participants in the NLST study 
(only 4.5%).  
B. Applicability  
Describe included participants, setting and dates:  
Retrospective analyses of secondary data from NLST (53,452 participants) and PLCO trials (80,672 
participants, never smokers were not considered), two RCTs conducted in the United States. 
Enrollment for PLCO was from November 1993-July 2001; enrollment for NLST was from 2002-2004, with 
a median follow-up time of 6.5 years 
Concern that the included participants and setting do not match 
the review question  
CONCERN:  
(low/ high/ unclear)  
 low 
Rationale of applicability rating:  
The purpose of the study was to estimate the performance of nine models in predicting lung cancer 
incidence and death, so the included participants and setting are appropriate. 
A potential problem specific to this systematic review is that models developed for specific ethnicities 
were not eligible for review (since they would not be broadly applicable). 
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DOMAIN 2: Predictors  
Covers potential sources of bias and applicability concerns related to the definition and measurement of 
predictors. Predictors are variables evaluated for their association with the outcome of interest; they are 
ultimately combined to form the prediction model 
 
A. Risk of Bias  
List and describe predictors included in the final model, e.g. definition and timing of assessment:  
 
Across all models, the following components were listed as predictors: age, various measures 
of smoking exposure (status, duration, cigarettes per day, pack-years smoked, time since 
cessation). 
 
Some models accounted for factors such as gender, race, ethnicity, BMI, presence of 
comorbid respiratory disease (COPD, pneumonia, or asbestos exposure), personal history of 
cancer, family history of cancer. 
 
Dev  Val  
2.1 Were predictors defined and assessed in a similar way for all participants? (in this case, 
were they defined similarly across all models?)  PN 
2.2 Were predictor assessments made without knowledge of outcome data?   PN 
2.3 Are all predictors available at the time the model is intended to be used? (in this case, 
were all predictors available for each model?)  N 
Risk of bias introduced by predictors or their assessment  
RISK:  
(low/ high/ unclear)  
 high 
Rationale of bias rating:  
This study used secondary data from two large-scale, national trials. The methods and results from these 
RCTs had already influenced the standard of lung cancer detection and management (and important 
pieces of health policy). Therefore, there is a chance that the investigators could have predicted the 
models that would have been most likely to accurately estimate the outcomes of lung cancer incidence 
and mortality (especially since most of the authors have done extensive work with disease modeling). 
There was also no uniform definition of the predictors across all models. Some models included 
predictors that did not have supporting data from the NLST and PLCO trials. In those instances, the 
investigators assumed no exposure (example=asbestos), which could lead to biased estimates (even if 
minimal). 
B. Applicability  
Concern that the definition, assessment or timing of predictors in the 
model do not match the review question  
CONCERN:  
(low/ high/ unclear)  
 low 
Rationale of applicability rating:  
The predictors in each model matched the review question, even though they were defined differently 






DOMAIN 3: Outcome  
Covers potential sources of bias and applicability concerns related to the definition and determination of 
the outcome 
 
A. Risk of Bias  
Describe the outcome, how it was defined and determined, and the time interval between predictor 
assessment and outcome determination:  
The outcome was lung cancer incidence and mortality. The RCTs (NLST and PLCO) that provided the 
data for this modeling study based their definition of lung cancer on radiography guidelines (which is in 
many ways dependent upon a radiologist’s interpretation). Furthermore, the studies used different forms 
of imaging (chest x-ray versus CT scan which each have different sensitivities for detection of lung 
cancer) to determine the outcome. Data were retrospectively obtained; the models were tested on their 
ability to predict 5 or 6-year lung cancer incidence and mortality. 
 Dev  Val  
3.1 Was the outcome determined appropriately?   Y 
3.2 Was a pre-specified or standard outcome definition used?   PY 
3.3 Were predictors excluded from the outcome definition?   Y 
3.4 Was the outcome defined and determined in a similar way for all participants? (in this 
case, was the outcome defined and determined in a similar way for all participants across all 
models?)  
PY 
3.5 Was the outcome determined without knowledge of predictor information?   PY 
3.6 Was the time interval between predictor assessment and outcome determination 
appropriate?   Y 
Risk of bias introduced by the outcome or its determination  
RISK:  
(low/ high/ unclear)  
 low 
Rationale of bias rating:  
Models were made with the intention of predicting either one-year, five-year, or six-year lung cancer 
incidence/mortality. Some information about predictors could have been known ahead of time since this 
was a retrospective analysis.  
B. Applicability  
At what time point was the outcome determined: This was a retrospective analysis, so the baseline lung 
cancer incidence and mortality rate for each trial was known ahead of time. However, each of the models 
was used to make predictions on 6-year incidence and mortality.  
If a composite outcome was used, describe the relative frequency/distribution of each contributing 
outcome: No composite outcome 
Concern that the outcome, its definition, timing or determination do 
not match the review question  
CONCERN:  
(low/ high/ unclear)  
 low 






DOMAIN 4: Analysis  
Examines whether key statistical considerations were correctly addressed 
 
Risk of Bias  
Describe numbers of participants, number of candidate predictors, outcome events and events per 
candidate predictor (for DEV only): N/A 
Describe how the model was developed (for example in regards to modeling technique (e.g. survival or 
logistic modeling), predictor selection, and risk group definition): N/A, validation study only 
Describe whether and how the model was validated, either internally (e.g. bootstrapping, cross validation, 
random split sample) or externally (e.g. temporal validation, geographical validation, different setting, 
different type of participants): Retrospective validation using data from two large-scale RCTs performed in 
the US 
Describe the performance measures of the model, e.g. (re)calibration, discrimination, (re)classification, 
net benefit, and whether they were adjusted for optimism: None of the models were re-calibrated to the 
NLST or PLCO data. Results for calibration, discrimination, and net benefit were reported.  
Calibration is reported as an intercept with a value of zero representing perfect calibration in the large; 
discrimination is reported as the area under the receiver operating characteristic curve (AUC) whereby 
values between 0.5 and 1.0 reflect sensible models; and the degree of clinical usefulness is described as 
the “net benefit over a range of risk thresholds” and is reported in terms of decision curve analyses. 
Describe any participants who were excluded from the analysis: non-applicable 
Describe missing data on predictors and outcomes as well as methods used for missing data:  
History of pneumonia was not reported for PLCO participants, so data from the NLST were used to 
impute history of pneumonia for PLCO participants. Analyses for this study were performed with multiple 
imputation of missing values. 
 Dev  Val  
4.1 Were there a reasonable number of participants with the outcome?   Y 
4.2 Were continuous and categorical predictors handled appropriately?   Y 
4.3 Were all enrolled participants included in the analysis?   Y 
4.4 Were participants with missing data handled appropriately?   Y 
4.5 Was selection of predictors based on univariable analysis avoided?    
4.6 Were complexities in the data (e.g. censoring, competing risks, sampling of controls) 
accounted for appropriately?   PY 
4.7 Were relevant model performance measures evaluated appropriately?   Y 
4.8 Were model overfitting and optimism in model performance accounted for?    
4.9 Do predictors and their assigned weights in the final model correspond to the results 
from multivariable analysis?    
Risk of bias introduced by the analysis  
RISK:  
(low/ high/ unclear)  
 low 








Reaching an overall judgment about risk of bias of the prediction model evaluation  
Low risk 
of bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external validation, and it was rated as low 
risk of bias for all domains, consider downgrading to high risk of bias. Such a model can 
only be considered as low risk of bias, if the development was based on a very large data set 
and included some form of internal validation.  
High risk 




If an unclear risk of bias was noted in at least one domain and it was low risk for all other 
domains.  
Reaching an overall judgment about applicability of the prediction model evaluation  
Low concerns 
regarding applicability  
If low concerns regarding applicability for all domains, the prediction model 
evaluation is judged to have low concerns regarding applicability.  
High concerns 
regarding applicability  
If high concerns regarding applicability for at least one domain, the prediction 
model evaluation is judged to have high concerns regarding applicability.  
Unclear concerns 
regarding applicability  
If unclear concerns (but no “high concern”) regarding applicability for at least one 
domain, the prediction model evaluation is judged to have unclear concerns 
regarding applicability overall.  
 
Overall judgment about risk of bias and applicability of the prediction model evaluation  
Overall judgment of risk of bias  
RISK:  
(low/ high/ unclear)  
 
Summary of sources of potential bias:  
There was no uniform definition of the predictors across all models. Some models included predictors that 
did not have supporting data from the NLST and PLCO trials. In those instances, the investigators 
assumed no exposure (example=asbestos), which could lead to biased estimates (even if minimal). 
 
Overall judgment of applicability  
CONCERN:  
(low/ high/ unclear)  
 
Summary of applicability concerns:  
The purpose of the study was to evaluate the performance of nine models in predicting lung cancer 
incidence and death. The predictors in each model matched the review question, even though they were 
sometimes defined differently across models. 
 
 
